PAK2 Antibody is affinity chromatography purified via peptide column.
Immunogen
Anti-PAK2 antibody was raised against a peptide corresponding to 14 amino acids near the carboxy terminus of human PAK2. The immunogen is located within amino acids 440-490 of PAK2.
PAK2
Reactivity: Human
WB, ELISA
Host: Rabbit
Polyclonal
unconjugated
Application Notes
WB: 0.5-1 μ,g/mL, IHC: 10 μ,g/mL, IF: 20 μ,g/mL.
Antibody validated: Western Blot in human, mouse and rat samples, Immunohistochemistry and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
PAK2 Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
PAK2 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
PAK2 Antibody: The p21-activated kinases (PAKs) are serine-threonine kinases that bind to the active forms of Cdc42 and Rac. They are divided into two groups, the first of which include PAK1, 2 and 3, and can be activated by Cdc42/Rac binding. Group 1 PAKs contain an autoinhibitory domain whose activity is regulated by Cdc42/Rac binding. The group 1 PAKs are known to be involved in cellular processes such as gene transcription, apoptosis, and cell morphology and motility. Much less is known about the second group, which includes PAK4, 5 and 6, and are not activated by Cdc42/Rac binding. Of the six PAK proteins, only PAK2 is ubiquitously expressed and cleaved by caspase-3. This cleavage removes the amino-terminal regulatory domain and generates a constitutively active kinase fragment. Recent experiments have shown that following cleavage, the active fragment is myristoylated and directed to the plasma membrane and membrane ruffles where it promotes cell death via increased signaling through the c-Jun N-terminal kinase pathway, but without compromising mitochondrial integrity.